Differential Effects of Isoflurane and Propofol on Upper Airway Dilator Muscle Activity and Breathing

Matthias Eikermann, M.D., Ph.D.,* Atul Malhotra, M.D.,† Philipp Fassbender, M.D.,‡ Sebastian Zaremba,‡ Amy S. Jordan, Ph.D.,§ Shiva Gautam, Ph.D.,∥ David P. White, M.D.,§ Nancy L. Chamberlin, Ph.D.**

Background: Anesthesia impairs upper airway integrity, but recent data suggest that low doses of some anesthetics increase upper airway dilator muscle activity, an apparent paradox. The authors sought to understand which anesthetics increase or decrease upper airway dilator muscle activity and to study the mechanisms mediating the effect.

Methods: The authors recorded genioglossus electromyogram, breathing, arterial blood pressure, and expiratory carbon dioxide in 58 spontaneously breathing rats at an estimated ED50 (median effective dose) of isoflurane or propofol. The authors further evaluated the dose–response relations of isoflurane under different study conditions: (1) normalization of mean arterial pressure, or end-expiratory carbon dioxide; (2) bilateral lesion of the Kölliker-Fuse nucleus; and (3) vagotomy. To evaluate whether the markedly lower inspiratory genioglossus activity during propofol could be recovered by increasing flow rate, a measure of respiratory drive, the authors performed an additional set of experiments during hypoxia or hypercapnia.

Results: In vagally intact rats, tonic and phasic genioglossus activity were markedly higher with isoflurane compared with propofol. Both anesthetics abolished the genioglossus negative pressure reflex. Inspiratory flow rate and anesthetic agent predicted independently phasic genioglossus activity. Isoflurane dose-dependently decreased tonic and increased phasic genioglossus activity, and increased flow rate, and its increasing effects were abolished after vagotomy. Impairment of phasic genioglossus activity during propofol anesthesia was reversed during evoked increase in respiratory drive.

Conclusion: Isoflurane compared with propofol anesthesia yields higher tonic and phasic genioglossus muscle activity. The level of respiratory depression rather than the level of effective anesthesia correlates closely with the upper airway dilator muscle function during anesthesia.

UPPER airway patency depends on an appropriate balance between the dilating force of pharyngeal muscles and the collapsing force of negative intraluminal pressure, which is generated by respiratory “pump” muscles. The genioglossus protects pharyngeal patency in humans. This muscle receives various types of neural drive, including a phasic (in phase with inspiration) and tonic (expiratory) drive, distributed differentially across the hypoglossal motoneuron pool. In addition, reflex genioglossus activation in response to negative pharyngeal pressure stabilizes upper airway patency both in humans and in rats. General anesthetic agents, including propofol and isoflurane, can predispose the upper airway to collapse, partly by decreasing upper airway muscle activity. In contrast, recent data suggest that anesthetics can increase genioglossus phasic activity, an apparent paradox. It is not clear which of these disparate observations—activation versus inhibition of upper airway dilator function—are anesthetic type/agent dependent or dependent on the study conditions. Understanding the mechanism by which anesthetics activate or inhibit upper airway dilator muscle activity is fundamental to their safe use in settings where upper airway patency is at risk, e.g., during conscious sedation.

In theory, anesthetics could affect upper airway dilator activity by several mechanisms, including the following. First, in humans, anesthetics induce a dose-dependent decrease in hypercapnic and hypoxic ventilatory drive. Therefore, the activity of hypoglossal motoneurons is in part respiratory related, a decrease in ventilatory drive could result in a suppression of hypoglossal motor activity. Second, anesthetics depress hypoglossal motoneurons, both directly and possibly indirectly by enhancing the activity of the inhibitory neurotransmitters γ-aminobutyric acid and glycine, receptor mechanisms that are tonically active at the hypoglossal motor nucleus. Third, animal studies have revealed barbiturates and volatile anesthetics can decrease skeletal muscle contractility, a condition that has been shown to activate phasic genio-
glossus activity. Fifth, the vagus nerve is important for mediating the interplay between lung volume and upper airway muscle activity. and isoflurane may have vagolytic effects. Finally, it has recently been suggested that volatile anesthetics can increase phasic hypoglossal nerve discharge by altering neuronal activity in the Kölliker-Fuse region, which contains hypoglossal premotor motoneurons.

Based on the observations of Roda et al., we tested the a priori hypothesis that phasic genioglossus muscle activity is higher during isoflurane anesthesia compared with propofol. We tested the secondary hypothesis that flow rate, a measure of respiratory drive, predicts the effects of anesthetics on phasic genioglossus activation. Third, with an exploratory intention, we sorted out the above mentioned variables which could mediate the effects of isoflurane at the genioglossus by controlling in subsets of experiments for carbon dioxide concentration, mean arterial blood pressure, Kölliker-Fuse neuron influence, or vagus nerve effects.

Materials and Methods

Every effort was made to minimize the numbers of animals used and their suffering. All procedures involving animals were approved by the Institutional Animal Care and Use Committee at Harvard Medical School, Boston, Massachusetts. Additional information is available on the ANESTHESIOLOGY Web site at http://www.anesthesiology.org.

Fifty-eight adult male Sprague-Dawley rats (300–400 g; Harlan Sprague-Dawley, Indianapolis, IN) were used in these studies. After induction of anesthesia with isoflurane, electromyographic recording electrodes were inserted into the genioglossus (one on each side of the midline by open surgery). The trachea was transected and cannulated with PE-240 tubing through which the rat spontaneously breathed and isoflurane was delivered. In a subset of six chronically instrumented rats, we did not perform tracheostomy but delivered isoflurane by facemask.

Measurements and Data Analysis

Genioglossus electromyography signals were amplified (Grass Instruments, West Warwick, RI), filtered, moving time averaged (100 ms), and digitized by a computer. Signals were analyzed with Clampfit (Molecular Devices, Sunnyvale, CA) and Igor Pro (WaveMetrics, Inc., Lake Oswego, OR). Phasic genioglossus activity was defined as the entire burst that occurred in phase with each inspiration minus the nadir inspiratory activity preceding it in the same respiratory cycle. Tonic genioglossus activity was defined as nadir genioglossus activity during expiration minus genioglossus activity measured in the dead rat after euthanasia (reflecting the degree of electrical noise).

Negative pressure was delivered to the rats’ isolated upper airway. For this purpose, the rats’ nares were occluded by a plastic cap placed over their muzzle and sealed with glue. Negative pressure was then applied via this cap by gating a vacuum source with a solenoid valve. The magnitude of the applied pressure was measured by a pressure-sensitive catheter (Millar Instruments, Houston, TX) inserted by the tracheostomy into the rostral trachea, which we sealed up with a suture subsequently. For evaluation of the negative pressure reflex, the change in genioglossus amplitude during negative pressure was measured by taking the average of the second, third, and fourth breaths after the onset of negative pressure application (4-s duration, delivered at a 20-s duty cycle) and comparing it with the average during the three breaths just before negative pressure application. In each rat, we applied a stimulus that produced a consistent increase in genioglossus activity (fig. E1 of the Web Enhancement). The negative pressure stimulus was kept constant throughout the experiment.

End-tidal carbon dioxide was measured by a CAPSTAR-100 Carbon Dioxide Analyzer (CWE Inc., Ardmore, PA), and intratracheal gas sampling was used to measure isoflurane gas concentration, as described by Pajewski et al. Samples were obtained consecutively in duplicate to ensure constant alveolar concentration, and averaged values were used for analysis. Gas samples were assayed using a side-stream infrared analyzer (Capnomac II; DATEX Instrumentarium Corp., Helsinki, Finland). Blood gas analyses of arterial blood samples were performed immediately after blood samples were taken (OPTI CCA-TS; Osometech, Roswell, GA).

Depth of anesthesia was determined by assessing responses to tail clamping. A clamp was applied to the base of the tail and oscillated (1–2 Hz) for up to 1 min or until the rat displayed gross and purposeful movement.

Protocols

The protocols applied in this study are depicted in figure 1.

Protocol 1. After surgery, we compared the effects of isoflurane (Baxter Healthcare, Deerfield, IL; n = 12) or propofol (AstraZeneca Pharmaceuticals, Wilmington, DE; n = 6) on genioglossus function.

Isoflurane-anesthetized Rats. After surgery during isoflurane anesthesia, we determined the ED_{50} (median effective dose) by applying a standardized noxious stimulus on the tail as previously described. Briefly, tail clamping was applied and, depending on the response, the isoflurane concentration was increased or decreased by 0.2%. This procedure was repeated every 10 min until two sequential responses just permitted and just prevented movement. This isoflurane level was taken as the ED_{50}. Anesthesia was stabilized at this level for 45 min before measurement of genioglossus activity was performed during basal breathing. We then established a
### Protocol 1:
- **Isoflurane**: n=12, 3 different doses.
- **Propofol**: n=6, ED50 only.

**None**

<table>
<thead>
<tr>
<th>Induction</th>
<th>Surgery</th>
<th>Intervention</th>
<th>Denomination of ED50</th>
<th>Measurement 1</th>
<th>Titration of analgesia</th>
<th>Measurement 2</th>
<th>Titration of analgesia</th>
<th>Measurement 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>ED 50: (Propofol: n=6, isoflurane: n=12)</td>
<td>Norm. breath.</td>
<td>NP</td>
<td>CO₂ Steady</td>
<td>Norm. breath.</td>
<td>NP</td>
</tr>
<tr>
<td>Blood pressure normalized (vasopressin, n=6)</td>
<td>ED 50 of isoflurane</td>
<td>Isoflurane 1%</td>
<td>Isoflurane 2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure normalized (phenylephrine, n=11)</td>
<td>Normal Breathing</td>
<td>NP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KF lesion (n=6)</td>
<td>Chronic instrumentation, 5 days recovery (n=6)</td>
<td>No anesthesia</td>
<td>Isoflurane 1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vagotomy (n=6)</td>
<td>Propofol ED50</td>
<td>Normal breathing</td>
<td>Hypoxia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Protocol 2

**Isoflurane, n=35**

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Measurement</th>
<th>Titration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure normalized</td>
<td>ED 50 of isoflurane</td>
<td>Isoflurane 1%</td>
</tr>
<tr>
<td>KF lesion (n=6)</td>
<td>Normal Breathing</td>
<td>NP</td>
</tr>
<tr>
<td>Vagotomy (n=6)</td>
<td>Chronic instrumentation, 5 days recovery (n=6)</td>
<td>No anesthesia</td>
</tr>
<tr>
<td>Chronic instrumentation, 5 days recovery (n=6)</td>
<td>Propofol ED50</td>
<td>Normal breathing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Protocol 3

**Propofol, n=6**

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Measurement</th>
<th>Titration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure normalized (vasopressin, n=6)</td>
<td>ED 50 of isoflurane</td>
<td>Isoflurane 1%</td>
</tr>
<tr>
<td>Blood pressure normalized (phenylephrine, n=11)</td>
<td>Normal Breathing</td>
<td>NP</td>
</tr>
<tr>
<td>KF lesion (n=6)</td>
<td>Chronic instrumentation, 5 days recovery (n=6)</td>
<td>No anesthesia</td>
</tr>
<tr>
<td>Vagotomy (n=6)</td>
<td>Chronic instrumentation, 5 days recovery (n=6)</td>
<td>No anesthesia</td>
</tr>
<tr>
<td>Chronic instrumentation, 5 days recovery (n=6)</td>
<td>Propofol ED50</td>
<td>Normal breathing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Fig. 1. Protocols.** Protocol 1: After surgery, we determined the ED₅₀ (median effective dose) of propofol or isoflurane to compare the effects of equianesthetic doses of these anesthetics on genioglossus activity and breathing. In isoflurane-anesthetized animals, we subsequently measured these variables at two additional dose levels, i.e., 1.49 ± 0.01 (ED₅₀) (n = 12) and either 2% or 2.25% (n = 6 each). Protocol 2: We evaluated the effects of different interventions on the dose–response relation of isoflurane at the genioglossus muscle and breathing. In a subset of 6 chronically instrumented animals, we compared the effect of light isoflurane anesthesia between wakefulness and light anesthesia (1% isoflurane). Protocol 3: We evaluated during propofol anesthesia the effects on genioglossus muscle electromyogram of conditions that increased respiratory drive (hypoxia and hypercapnia) to flow rate values that were similar to those observed during isoflurane anesthesia. CO₂ = carbon dioxide; KF = Kölliker-Fuse nucleus; NP = negative pharyngeal pressure application.

---

**Propofol-anesthetized Rats.** After induction of anesthesia and surgery with isoflurane, we reduced the level to 1% isoflurane for 30 min, and recorded genioglossus function during 1% isoflurane. We then discontinued isoflurane administration and started an infusion of propofol (500 µg · kg⁻¹ · min⁻¹). After isoflurane had been discontinued for 45 min, we determined the ED₅₀ of propofol as described by Orth et al.³¹

---

**Protocol 2.** Because we had observed in protocol 1 that isoflurane increases phasic genioglossus activity in the 1- to 2-vol% range, we applied additional interventions in subsets of rats and analyzed their effect on the dose–response curve of isoflurane.

Isoflurane dose-dependently decreases arterial blood pressure, as depicted in figure E3 of the Web Enhancement. Therefore, mean arterial blood pressure was normalized to values observed at 1% isoflurane, i.e., to a mean arterial pressure of 115 mmHg, by giving either phenylephrine (n = 11) or vasopressin (n = 6).

In six animals, we performed bilateral lesions of the Kölliker-Fuse neurons with orexin-saporin¹⁰ and studied the effects of isoflurane on genioglossus function 7–10 days later. Kölliker-Fuse nuclei were assumed at the following coordinates: anterior–posterior plane: 8.8 mm posterior of bregma; dorsoventral plane: 6.6 mm ventral of the brain surface; right–left plane: 2.6 mm left and right of midline as coordinates of Kölliker-Fuse nucleus. Injections were performed during chloral hydrate anesthesia (350 mg/kg), and orexin-saporin (90 nl; Advanced Targeting Systems, San Diego, CA) was injected by using a fine glass pipette. Injection volumes were monitored by measuring the movement of the fluid meniscus with...
an operating microscope equipped with an eyepiece reticule. The correct location of the Kölliker-Fuse neuron lesions was verified by post hoc histology (fig. E4 of the Web Enhancement).

In six rats, we performed an acute bilateral cervical vagotomy before studying the dose–response relation of isoflurane. After a medial cervical cutaneous incision, the vagus nerves were isolated from adjacent vascular structures and sectioned under a binocular microscope.

To compare the effects of isoflurane on genioglossus activity with unmedicated conditions, we chronically instrumented six rats with genioglossus electromyography electrodes. After recording of genioglossus baseline activity during quiet wakefulness/sleep for 5 min, anesthesia was induced with isoflurane and stabilized over a period of 45 min to achieve an end-tidal isoflurane concentration of 1%.

Protocol 3. In another subset of experiments, which aimed to determine whether suppression of phasic genioglossus activity by propofol could be reversed by conditions that restore respiratory drive, we produced hypoxemia (inspiratory oxygen concentration of 0.15) or hypercapnia (by adding nitrogen or carbon dioxide to the inspired air) during propofol anesthesia (ED50). Hypoxemia and hypercapnia were applied to each rat in a random order. The degree of hypoxemia and hypercapnia was titrated to normalize genioglossus activity in each rat to the level observed previously during isoflurane (1 vol%) anesthesia. The effects of the intervention were quantified by arterial blood gas analyses taken before the evoked increase in respiratory drive and 180 s after the target level was set.

Statistical Analysis
The primary outcome was phasic genioglossus activity. We used the peak moving time average for statistical analysis, unless indicated otherwise. Rats studied in protocol 1 were included for testing the primary hypothesis, that phasic genioglossus activity is higher during isoflurane anesthesia compared with propofol anesthesia (ED50). Hypoxemia and hypercapnia were applied to each rat in a random order. The degree of hypoxemia and hypercapnia was titrated to normalize genioglossus activity in each rat to the level observed previously during isoflurane (1 vol%) anesthesia. The effects of the intervention were quantified by arterial blood gas analyses taken before the evoked increase in respiratory drive and 180 s after the target level was set.

Data from 18 rats anesthetized with an ED50 of isoflurane (n = 12) or propofol (n = 6) were analyzed (protocol 1). The ED50 of isoflurane amounted to 1.49 ± 0.01 vol%.

Phasic and tonic genioglossus activities were markedly and significantly higher during isoflurane anesthesia compared with an equivalent dose of propofol (infusion rate: 880 ± 41 μg · kg⁻¹ · min⁻¹; figs. 2A and B). At ED50 of isoflurane and propofol, the genioglossus negative pressure reflex was eliminated.

End-tidal carbon dioxide was significantly lower in isoflurane-anesthetized rats compared with propofol, amounting to 41 ± 1 versus 81.8 ± 2.6 mmHg (P < 0.05). Respiratory rate was significantly higher in isoflurane-anesthetized rats compared with propofol, amounting to 80 ± 2 versus 48 ± 8.3 breaths/min (P < 0.05), and tidal volume tended to be higher (P = 0.08), amounting to 1.84 ± 0.08 versus 1.48 ± 0.05 ml, respectively.

During ED50 of propofol and isoflurane, heart rate (317 ± 10 vs. 330 ± 9 beats/min) and mean arterial pressure (94 ± 8.6 vs. 85 ± 7.4 mmHg) did not differ significantly between isoflurane- and propofol-anesthetized rats.

Secondary Hypothesis: Association between the Effects of Anesthetics on Flow Rate and Phasic Genioglossus Activity
Inspiratory flow rate (tidal volume/inspiratory time) was positively correlated with phasic genioglossus activ-
Phasic genioglossus activity and flow rate in-creased with increasing isoflurane concentration in the 1- to 2-vol% range, (fig. 3), and the increase in flow rate observed with increasing isoflurane concentrations from 1% to 2% correlated significantly with the paralleled increase in rate of rise of phasic genioglossus activity ($r = 0.47; P < 0.05$).

In propofol-anesthetized rats, comparison of phasic genioglossus activity during evoked hypoxemia and hypercapnia (conditions that increased respiratory drive) with control conditions revealed a significant ($P < 0.05$) interaction of the intervention (evoked hypoxemia and hypercapnia; fig. 5, protocol 3). The decreasing effects of propofol on inspiratory genioglossus muscle function were fully reversed to baseline levels (1% isoflurane level) when flow rate and minute ventilation were restored with carbon dioxide (end-tidal carbon dioxide tension $= 134 \pm 7$ mmHg), and partially reversed with hypoxemia (end-tidal oxygen tension $= 44 \pm 2$ mmHg).

Analysis of all data derived during ED 50 of isoflurane and propofol anesthesia (protocols 1–3) revealed that flow rate ($F = 67.32, P < 0.001$) and anesthetic agents ($F = 35.2, P = 0.004$) independently predicted phasic genioglossus activity.

In propofol-anesthetized rats, comparison of phasic genioglossus activity during evoked hypoxemia and hypercapnia (conditions that increased respiratory drive) with control conditions revealed a significant ($P < 0.05$) interaction of the intervention (evoked hypoxemia and hypercapnia; fig. 5, protocol 3). The decreasing effects of propofol on inspiratory genioglossus muscle function were fully reversed to baseline levels (1% isoflurane level) when flow rate and minute ventilation were restored with carbon dioxide (end-tidal carbon dioxide tension $= 134 \pm 7$ mmHg), and partially reversed with hypoxemia (end-tidal oxygen tension $= 44 \pm 2$ mmHg).

Analysis of all data derived during ED 50 of isoflurane and propofol anesthesia (protocols 1–3) revealed that flow rate ($F = 67.32, P < 0.001$) and anesthetic agents ($F = 35.2, P = 0.004$) independently predicted phasic genioglossus activity.

In propofol-anesthetized rats, comparison of phasic genioglossus activity during evoked hypoxemia and hypercapnia (conditions that increased respiratory drive) with control conditions revealed a significant ($P < 0.05$) interaction of the intervention (evoked hypoxemia and hypercapnia; fig. 5, protocol 3). The decreasing effects of propofol on inspiratory genioglossus muscle function were fully reversed to baseline levels (1% isoflurane level) when flow rate and minute ventilation were restored with carbon dioxide (end-tidal carbon dioxide tension $= 134 \pm 7$ mmHg), and partially reversed with hypoxemia (end-tidal oxygen tension $= 44 \pm 2$ mmHg).

Analysis of all data derived during ED 50 of isoflurane and propofol anesthesia (protocols 1–3) revealed that flow rate ($F = 67.32, P < 0.001$) and anesthetic agents ($F = 35.2, P = 0.004$) independently predicted phasic genioglossus activity.
Characterization of Different Interventions on the Dose-Response Relation of Isoflurane at the Genioglossus Muscle

Analysis of data derived from protocol 1 revealed that isoflurane in the 1- to 2 vol% range dose-dependently increased phasic genioglossus activity (protocol 1; F = 4.99, P < 0.05). In contrast, at the highest dose level of isoflurane studied (2.25 vol%), genioglossus activity was significantly (paired t test) lower compared with values observed at 1.5% (figs. 3A and fig. E5 of the Web Enhancement, protocol 1). During light isoflurane anesthesia (1.0 vol% end-tidal), we measured a robust genioglossus negative pressure reflex (increased phasic genioglossus activity in response to negative pressure pulse) to 118 ± 8% of values observed before negative pressure application (fig. 6A). The genioglossus response to negative laryngeal pressure application decreased significantly (P < 0.05) with increasing isoflurane doses. Isoflurane dose-dependently increased end-tidal carbon dioxide concentration, amounting to 39 ± 0.8, 41 ± 1, and 46.6 ± 1.8 mmHg under 1, 1.5, and 2% isoflurane, respectively (fig. E2 of the Web Enhancement, protocol 1). Increasing end-tidal carbon dioxide concentration to 50 mmHg (the highest level observed) increased phasic genioglossus activity at 1% isoflurane to 40.8 ± 4.1 μV (end-tidal carbon dioxide = 50 mmHg) versus 35.8 ± 2.5 μV (carbon dioxide = 41 ± 1 mmHg; P < 0.05). With carbon dioxide held constant, isoflurane still dose-dependently increased phasic genioglossus activity in the 1-2% range (40.8 ± 4.1, 48.3 ± 14.1, and 55.1 ± 24.16 μV at 1, 1.5, and 2% isoflurane, respectively; fig. E2 of the Web Enhancement). These values were not significantly different from those of control animals.

In chronically instrumented, awake animals (protocol 2), respiratory rate amounted to 90 ± 4.8 breaths/min, and decreased significantly (paired t test) to 64 ± 3.9 breaths/min during isoflurane anesthesia (1 vol%). Tonic genioglossus activity decreased with isoflurane anesthesia compared with the unmedicated condition, and decreased further with increasing isoflurane concentrations (P < 0.05 for dose effect; figs. 6B and C). Phasic genioglossus activation was small and variable in unmedicated awake rats but always appeared in the presence of isoflurane (fig. E5 of the Web Enhancement).

Isoflurane dose-dependently decreased mean arterial blood pressure from 119 ± 17 mmHg at 1 vol% to 99 ± 4 mmHg at 2 vol% (protocol 1). In rats in which mean arterial pressure was normalized to values observed at 1 vol%, either by phenylephrine or by vasopressin (protocol 2), isoflurane dose-dependently increased phasic genioglossus activity as it did in control rats (fig. E3 of the Web Enhancement).

In Körlliker-Fuse-lesioned rats (protocol 2; for histology, see fig. E4 of the Web Enhancement), isoflurane dose-dependently increased phasic genioglossus activity as it did in control animals.

Discussion

Genioglossus activity is higher during isoflurane compared with propofol anesthesia at equianesthetic doses, and effects of anesthetics on phasic genioglossus activity resemble those on flow rate. Isoflurane dose-dependently decreases tonic and increases phasic genioglossus activity, effects that persist with normalization of carbon dioxide and arterial blood pressure and Kölliker-Fuse...
Fig. 4. Influence of vagal nerve section on genioglossus activity and breathing. Open circles = vagal nerves intact; diamonds = vagotomized rats. Data are mean ± SEM. * $P < 0.05$ for dose effects of isoflurane (within groups). # $P < 0.05$ versus controls (between-subjects effects). (A) Phasic genioglossus activity. At 1% isoflurane, phasic genioglossus activity was significantly higher in vagotomized rats compared with controls. Isoflurane increased genioglossus activity dose dependently in controls, whereas it decreased it in vagotomized rats. (B) Flow rate. At 1% isoflurane, flow rate was significantly higher in vagotomized rat compared with controls.

Fig. 5. Effects of hypoxemia and hypercapnia on phasic genioglossus activity, and flow rate during propofol anesthesia (ED$_{50}$ [median effective dose]). Arterial partial pressures of carbon dioxide and oxygen concentration were measured at time of assessment (mean and SEM). * $P < 0.05$ versus condition 1 (paired $t$ test). CO$_2$ = carbon dioxide; et = end-tidal; O$_2$ = oxygen. (A) Phasic genioglossus activity. Genioglossus activity increased significantly during evoked hypoxemia and hypercapnia. (B) Flow rate (tidal volume/inspiratory time). Flow rate increased significantly during evoked hypoxemia and hypercapnia. (C) Minute ventilation. Minute ventilation decreased significantly during propofol anesthesia and increased subsequently during evoked hypoxemia and hypercapnia. * $P < 0.05$ versus before evoked hypoxemia/ hypercapnia.

Association of Effects of Anesthetics on Flow Rate and Genioglossus Activity

The increasing effect of isoflurane on inspiratory drive seemingly accounts for the relatively preserved genioglossus phasic activity compared with propofol. This effect was abolished in vagotomized rats, where isoflurane dose-dependently decreased both the flow rate and genioglossus phasic activity, consistent with previous reports. Therefore, our data contribute to a better understanding of the “paradox” of an increasing versus decreasing effects of anesthetics on phasic genioglossus activity. The vagus nerve is important for mediating the interplay between lung volume and upper airway muscle activity, and lung inflation decreases genioglossus muscle activity, an effect that is mediated by the vagus nerve as the afferent pathway. We speculate that isoflurane increases phasic genioglossus activity by increasing flow rate, possibly by a vagolytic mechanism. However, differences in flow rate do not account completely for the differences in phasic genioglossus activation observed between anesthetics. Anesthetic agent type also explains some variance of phasic genioglossus activity independently of its effects on flow rate by an unidentified mechanism.

Anesthesiology, V 108, No 5, May 2008
Our data show that the increasing effects of isoflurane on inspiratory genioglossus activity are not consequences of its decreasing effects on arterial blood pressure or its increasing effects on carbon dioxide concentration. The genioglossus effects of isoflurane also persisted when Kölliker-Fuse nucleus was lesioned. Therefore, although our data support the findings of Roda et al.\textsuperscript{10} suggesting that intravenous anesthetics reduce hypoglossal activity much more than volatile anesthetics,\textsuperscript{10} our study contradicts their hypothesis that these changes are mediated by premotor neurons in the Kölliker-Fuse; in the study of Roda et al.,\textsuperscript{10} halothane was strongly associated with a robust phasic inspiratory activity in the hypoglossal nerve. It seems likely that the Kölliker-Fuse activation observed after halothane anesthesia\textsuperscript{10} was not causative for the effects of halothane on upper airway dilator muscle activity.

**Effects of Anesthetics on Genioglossus Reflex Activation**

Genioglossus muscle activity in rats increases in response to negative pressure in the upper airway.\textsuperscript{35–37} as it does in humans.\textsuperscript{38,39} In accord, we observed during light isoflurane anesthesia (1 vol%; fig. 6) a strong reflex activation of the genioglossus in response to negative pressure in the upper airway. This reflex was abolished at anesthetic doses of propofol and isoflurane and, in the case of isoflurane, at a dose range that nonetheless increased phasic genioglossus activity. Therefore, we suggest that effects of anesthetics on phasic and reflex activation of the genioglossus are induced by different mechanisms.

**Limitations**

The effects of anesthetics on respiratory muscles differ between species,\textsuperscript{40} and it is unclear whether our finding, preserved upper airway dilator muscle activity during isoflurane, translates to humans. Comparative studies on differential effects of equianesthetic concentrations of anesthetics on upper airway muscle patency are clearly needed.

A major difference between the animal preparation used in the current study and other studies undertaken in humans is that the upper airway has been bypassed in the current model. This means that there will be minimal respiratory-related changes in flow or pressure within the upper airway, and activation of pharyngeal/laryngeal mechanoreceptors by these stimuli. Because the tracheostomized animal preparation used in this study is less physiologic than models in which an animal breathes \textit{via} the intact upper airway, we adopted an additional protocol of chronically instrumented rats breathing by the normal route. Interestingly, the phasic and tonic genioglossus activity observed in these rats during 1% isoflurane was almost identical to the values observed in tracheostomized animals, suggesting that the anesthesia-related changes in electromyographic activity were central in origin.

We did not measure upper airway collapsibility. It is likely, though, that the marked depressive effects of propofol on the muscles of the upper airway (genioglossus) would increase the propensity of the upper airway to collapse compared with isoflurane anesthesia. Phasic genioglossus activation increases the size of the airway\textsuperscript{41} and decreases collapsibility,\textsuperscript{42} and may be of particular importance under conditions where the negative pressure reflex is absent. We have recently shown by magnetic resonance imaging that a quantitatively similar decrease in respiratory genioglossus activity in rats is associated with marked decreases in inspiratory upper airway volume.\textsuperscript{29}
Possible Clinical Implications

Some studies in humans suggest that subhypnotic concentrations of propofol have stronger decreasing effects on upper esophageal sphincter resting tone than isoflurane, whereas other data suggest the opposite. To our knowledge, it is unclear what the effects of equianesthetic concentrations of propofol and isoflurane on upper airway dilator muscle function might be. Our data suggest that respiratory depressant doses, rather than equivalent anesthetic doses, of anesthetics most likely determine the level of vulnerability of the airway dilator muscle function. Propofol in rats is more respiratory depressant than isoflurane given at equianalgesic doses, which seems to be similar in humans, during anesthesia, and during sedation under spontaneous ventilation. If our results obtained in rats translate to the clinical situation of patients scheduled to undergo surgery, then the choice of the anesthetic agent might influence the safety of patients with airways unprotected by an endotracheal tube or a laryngeal mask, during conscious sedation, or in extubated patients recovering from general anesthesia.

The strong impairing effects of propofol on upper airway dilator muscle function were reversed by carbon dioxide administration, which increased respiratory drive. It would be interesting to know whether upper airway dilator muscle function can be restored by increasing respiratory drive in humans by administering low doses of carbon dioxide to the inspiration air, e.g., using dead space or rebreathing or with other respiratory stimulants. The depressive effects of isoflurane on hypoxic and hypercapnic ventilatory response can be reversed by antioxidant administration. Volatile anesthetics can increase reactive oxygen species production, and antioxidants reverse the reduction of the hypoxic ventilatory response by isoflurane. Therefore, it might be interesting to study whether some of the impairing effects of anesthetics on phasic genioglossus activity and respiratory drive observed in our study could be reversed by antioxidant treatment.

In summary, our data show that isoflurane compared with propofol anesthesia allows higher tonic and phasic genioglossus muscle activity at equianesthetic doses, but both anesthetics abolish its reflex activation. The level of respiratory depression rather than the level of effective anesthesia correlates closely with the airway dilator muscle function during anesthesia.

The authors thank Carl Rosow, M.D., Ph.D. (Professor of Anesthesia), Jeeverandra Martyn, M.D. (Professor of Anesthesia, Department of Anesthesia, Massachusetts General Hospital, Boston, Massachusetts), and Julian Saboisky, Ph.D. (Research Fellow in Medicine, Division of Sleep Medicine, Brigham and Women’s Hospital, Boston, Massachusetts), for their useful comments and criticism. The authors thank Quan Ha (Research Assistant, Beth Israel Deaconess Medical Center, Boston, Massachusetts) for excellent technical support.

References


